Alzheon’s peer-reviewed data tie a falling blood marker to slower memory and brain decline in patients taking its daily pill.
A spinal tap isn’t something most older adults sign up for twice a year just to see if a drug is working. Brain scans aren’t much easier: booking one, paying for one, sitting still for one. So when researchers found a blood marker that could stand in for both, it quietly became one of the more useful tools in Alzheimer’s research. The marker is a protein fragment called p-tau217.
On 8 September, the Framingham, Massachusetts biotech Alzheon published peer-reviewed data arguing that its pill, valiltramiprosate (known in development as ALZ-801), pushes that marker down and keeps it down [1].
Alzheimer’s tends to sit a little apart from the rest of longevity science, mostly because it’s the condition people fear most about aging in the first place. It doesn’t just shorten life; it can hollow out the years before that. A treatment that’s swallowed rather than infused, and checked through a routine blood draw instead of a scan or a lumbar puncture, would make it realistic to monitor far more people as populations gray. That’s the practical hook here, and it’s worth sitting with before getting into the numbers.
The new paper, published in the journal Drugs, folds together two separate studies. One is the Phase 3 APOLLOE4 trial, run in people who carry two copies of the APOE4 gene, the highest-risk group for Alzheimer’s. The other is an earlier Phase 2 study that included people with either one or two copies. Putting them side by side let Alzheon’s team ask whether the biomarker changes actually held up across trials, not just within one.
They mostly did. Across the full Phase 3 population, plasma p-tau217 started out roughly even between drug and placebo groups, then diverged: by weeks 26, 52 and 78, levels were significantly lower on valiltramiprosate (p<0.025 each time). Patients with mild cognitive impairment specifically showed the same pattern, statistically significant at weeks 52 and 78. The mild Alzheimer’s subgroup only trended in that direction without reaching significance, worth flagging rather than glossing over.
What makes the blood marker findings more convincing is what they lined up with in real life. Before treatment even started, patients with mild cognitive impairment who had higher p-tau217 levels also tended to have more advanced disease. They scored worse on standard memory and thinking tests, had a smaller hippocampus (the brain’s memory center), and had thinner tissue in the brain’s outer layer, the area most linked to thinking skills. None of that was a coincidence; the connections were strong enough to be statistically meaningful.
Then, once patients started taking the drug, the same pattern showed up in reverse. Patients whose p-tau217 levels dropped the most by week 78 also lost less ground on memory and daily-function tests, and their hippocampus shrank less than in patients whose levels barely moved. A second blood marker, called neurofilament light chain, backed this up: it stayed essentially flat over the 78 weeks in patients taking the drug, while it kept climbing in patients on placebo. That marker’s movement also tracked with both better memory scores and the p-tau217 changes.
“These results provide direct biological evidence that valiltramiprosate engages its molecular target by inhibiting formation of neurotoxic soluble amyloid oligomers, reducing amyloid aggregation and producing measurable downstream effects on tau hyperphosphorylation and neurodegeneration,” said John A. Hey, Alzheon’s chief scientific officer and the paper’s lead author.
It’s a different mechanism than the injectable amyloid antibodies that have gotten most of the recent Alzheimer’s coverage. Those drugs mostly clear plaques after they’ve already formed. Valiltramiprosate is designed to work a step earlier, stopping small toxic amyloid clusters from clumping together in the first place. Alzheon has pointed to that as a possible reason for a safety result it keeps highlighting: no increase in brain swelling (called ARIA-E) versus placebo, and no symptomatic cases at all, a complication that has dogged some antibody therapies, particularly in the APOE4/4 group most likely to develop it.
“Valiltramiprosate has emerged as one of the few late-stage treatments with the potential to meaningfully change Alzheimer’s therapy in the near term,” said Martin Tolar, Alzheon’s founder, president and chief executive.
Meanwhile, Anton Porsteinsson of the University of Rochester, an outside researcher not involved in developing the drug, pointed specifically to the consistency of the MCI signal, saying it and related findings “strengthen the biological rationale for intervening upstream in the amyloid pathway.”
APOE4/4 carriers make up around 15% of Alzheimer’s patients, and they’re who this drug has targeted first. Alzheon says it’s now planning its next Phase 3 trial, while also looking at whether the same approach can help the much larger group of people who carry just a single copy of APOE4.
